The Greater Cannabis Company, Inc. (GCAN)
OTCMKTS: GCAN · Delayed Price · USD
0.0007
0.00 (0.00%)
Jul 23, 2024, 4:00 PM EDT - Market open
GCAN Employees
The Greater Cannabis Company had 1 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
1
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$189,945
Market Cap
512.85K
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
GCAN News
- 5 months ago - GCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy - GlobeNewsWire
- 10 months ago - GCANRx Featured in American Journal of Endocannabinoid Medicine - GlobeNewsWire
- 1 year ago - GCANRx Announces Approval of Phase II Clinical Trial to Treat Autism Related Spectrum Disorders - GlobeNewsWire
- 1 year ago - GCANRx Announces Submission of Phase 2 Clinical Trial Application to Treat Autism Related Spectrum Disorders - GlobeNewsWire
- 2 years ago - GCANRx Strategic Advisor Dr. Adi Aran to be Interviewed by Dr. Sanjay Gupta on CNN Cannabis Special - GlobeNewsWire
- 2 years ago - GCANRx Appoints Renowned Cannabinoid Researcher Dr. Adi Aran as Strategic Advisor - GlobeNewsWire
- 2 years ago - GCANRx Announces Initiation of Preclinical Study for Neuropsychiatric Cannabinoid Therapy - GlobeNewsWire
- 3 years ago - GCANRx Signs Licensing Agreement with Shaare Zedek Scientific for Innovative Neuropsychiatric Cannabinoid Therapy - GlobeNewsWire